ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2020
Medical Care Costs Associated with Cancer Survivorship in the United States.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07410689 (SAFE.AI), which is not on this map. Cited by 332 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
SAFE.AI: Developing and Testing an AI-based Hybrid Chatbot for Financial Empowerment in Rural Cancer Care
Who cites it
332 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Effectiveness of eHealth interventions in long-term follow-up care for breast and gynecological cancer survivors: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Pooled it
- Systematic Review of Genomic-Based Risk Stratification in Localised Prostate Cancer Treatment Optimisation: Clinical Impact and Health Economic Evidence.Cancer medicine · 2026Pooled it
- From economic burden to patient-centered solutions: the evolving landscape of financial toxicity in oncology.Frontiers in public health · 2026Pooled it
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2024 for the treatment of colorectal cancer.International journal of clinical oncology · 2025Guideline
- The role of minimally invasive surgery within a multidisciplinary approach for patients with metastatic spine disease over a decade: A systematic review.Neuro-oncology · 2024Pooled it
- Influence of variables on breast self-examination: Potential barrier or enhancement of breast cancer prevention.Breast disease · 2024Pooled it
- Health Insurance Literacy Improvements Among Recently Diagnosed Adolescents and Young Adults With Cancer: Results From a Pilot Randomized Controlled Trial.JCO oncology practice · 2024Trial
- Trial
- Estimating True Patient Cost-Sharing Burden: Multi-Payer Claim Reconciliation in an All-Payer Claims Database.Medical care research and review : MCRR · 2026Article
- Patterns of Colorectal Cancer Diagnosis in Older Adults: A SEER-Medicare Analysis of Health and Economic Impact of Missed Screening Opportunities.Journal of surgical oncology · 2026Article
- PSMA-Targeted Liposomes for Therapeutic Delivery into a Prostate Cancer Cell Model.Pharmaceutics · 2026Article
- Cost-effectiveness of liquid biopsy screening for gastric cancer in the United States.JNCI cancer spectrum · 2026Article
- Development and validation of a human-supervised AI-augmented living oncology evidence platform: a breast cancer pilot study.ESMO real world data and digital oncology · 2026Article
- Medicaid Expansion and Mortality Among Patients With Colorectal Cancer.JAMA network open · 2026Article
- Private equity acquisitions and cancer care: nothing to see here? Not so fast.Journal of the National Cancer Institute · 2026Article
- From optimistic to overwhelmed: exploring health beliefs and barriers to oral anticancer medication adherence among cancer survivors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- How Much Chronic Disease Out-of-Pocket Expenditure Runs Through Pain? A Prospective Counterfactual Decomposition of Five-Year Korean Panel Data.Medicina (Kaunas, Lithuania) · 2026Article
- Article
- Economic Considerations in the Management of Superficial Bladder Cancer.The Urologic clinics of North America · 2026Review
- A Cost-Effectiveness Model of Semaglutide 2.4 mg, Resmetirom 80 mg, and Resmetirom 100 mg Versus Standard of Care for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis in the United States.PharmacoEconomics · 2026Article
272 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe prevalence of cancer survivorship is increasing. In this study, we provide contemporary population-based estimates and projections of the overall and site-specific cancer-attributable medical care costs in the United States.
methodsWe identified survivors aged ≥65 years diagnosed with cancer between 2000 and 2012 from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database and used 2007 to 2013 claims to estimate costs by cancer site, phases of care, and stage at diagnosis. Annualized average cancer-attributable costs for medical care (Medicare Parts A and B) and oral prescription drugs (Medicare Part D) were estimated by subtracting costs between patients with cancer and matched controls. Costs are reported in 2019 U.S. dollars. We combined phase-specific attributable costs with prevalence projections to estimate national costs from 2015 through 2030.
resultsOverall annualized average costs were highest in the end-of-life-cancer death phase, followed by the initial and continuing phases (medical care: $105,500, $41,800, and $5,300 and oral prescription drugs: $4,200, $1,800, $1,100, respectively). There was considerable variation in costs by cancer site and stage. Overall national costs in 2015 were $183 billion and projected to increase 34% to $246 billion by 2030, based only on population growth.
conclusionsPhase of care cancer-attributable cost estimates by cancer site and stage are key inputs for simulation models and cost-effectiveness analyses. IMPACT: The national cancer-attributed medical care costs in the United States are substantial and projected to increase dramatically by 2030, due to population changes alone, reflecting the rising burden of cancer care among cancer survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.